Improving human immunity to malaria

Public release date: 1-Aug-2012
[ | E-mail | Share ]

Contact: Sarah Jackson
press_releases@the-jci.org
Journal of Clinical Investigation

The deadliest form of malaria is caused the protozoan Plasmodium falciparum. During its life-cycle in human blood, the parasite P. falciparum expresses unique proteins on the surface on infected blood cells. Antibodies to these proteins are associated with protection from malaria, however, the identity of surface protein(s) that elicit the strongest immune response is unknown. Dr. James Beeson and colleagues at the Walter and Eliza Hall Institute of Medical Research in Victoria, Australia have developed novel assays with transgenic P. falciparum expressing modified surface proteins, allowing the researchers to quantify serum antibodies to surface proteins among malaria-exposed children and adults. They found that most of the human antibody response to the surface proteins targets a parasite protein known as PfEMP1. Moreover, the showed that people with PfEMP1-specific antibodies had a reduced risk of malaria symptoms, whereas antibodies to other surface antigens were not associated with protective immunity. These findings suggest antibodies against PfEMP mediate human immunity to malaria and have implications for future malaria vaccine development.

###

TITLE:

Targets of antibodies against Plasmodium falciparum-infected erythrocytes in malaria immunity

AUTHOR CONTACT:

James Beeson

Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, UNK, AUS

Phone: 613-9345-2555; Fax: 613-9347-0852; E-mail: beeson@wehi.edu.au

View this article at: http://www.jci.org/articles/view/62182?key=ed28073b9acd36ff3e6e

---

[ | E-mail | Share ]

?

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Public release date: 1-Aug-2012
[ | E-mail | Share ]

Contact: Sarah Jackson
press_releases@the-jci.org
Journal of Clinical Investigation

The deadliest form of malaria is caused the protozoan Plasmodium falciparum. During its life-cycle in human blood, the parasite P. falciparum expresses unique proteins on the surface on infected blood cells. Antibodies to these proteins are associated with protection from malaria, however, the identity of surface protein(s) that elicit the strongest immune response is unknown. Dr. James Beeson and colleagues at the Walter and Eliza Hall Institute of Medical Research in Victoria, Australia have developed novel assays with transgenic P. falciparum expressing modified surface proteins, allowing the researchers to quantify serum antibodies to surface proteins among malaria-exposed children and adults. They found that most of the human antibody response to the surface proteins targets a parasite protein known as PfEMP1. Moreover, the showed that people with PfEMP1-specific antibodies had a reduced risk of malaria symptoms, whereas antibodies to other surface antigens were not associated with protective immunity. These findings suggest antibodies against PfEMP mediate human immunity to malaria and have implications for future malaria vaccine development.

###

TITLE:

Targets of antibodies against Plasmodium falciparum-infected erythrocytes in malaria immunity

AUTHOR CONTACT:

James Beeson

Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, UNK, AUS

Phone: 613-9345-2555; Fax: 613-9347-0852; E-mail: beeson@wehi.edu.au

View this article at: http://www.jci.org/articles/view/62182?key=ed28073b9acd36ff3e6e

---

[ | E-mail | Share ]

?

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Source: http://www.eurekalert.org/pub_releases/2012-08/joci-ihi072412.php

ryan madson louisiana primary syracuse basketball chipper jones chipper jones dancing with the stars cast mickael pietrus